Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM

Launched by ASIAN INSTITUTE OF GASTROENTEROLOGY, INDIA · Apr 25, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at two medications, Vonaprazan and Esomeprazole, to see which one helps heal a condition called reflux esophagitis in patients who have undergone a treatment for achalasia called Peroral Endoscopic Myotomy (POEM). Reflux esophagitis occurs when stomach acid irritates the esophagus, and it can cause symptoms like heartburn and regurgitation. The trial aims to compare how well these two medicines work over an 8-week period, with Vonaprazan being a new option that might provide better acid control than the standard treatment, Esomeprazole.

To participate in this study, individuals must be at least 18 years old and have had the POEM procedure, confirmed to have moderate to severe reflux esophagitis, and have experienced reflux symptoms for at least four weeks. Participants will be asked to take one of the medications and report their symptoms and any side effects they experience. This trial is currently not recruiting participants, so it’s important to stay tuned for updates if you or someone you know might be interested in taking part.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years
• • History of POEM for achalasia
• • Endoscopic confirmation of LA grade B, C, or D reflux esophagitis at 3 months post-POEM
• • GERD symptoms (heartburn, regurgitation) for ≥4 weeks
• • Willingness to provide informed consent and comply with study procedures
• Exclusion Criteria:
• • History of prior anti-reflux surgery
• • Presence of Barrett's esophagus, esophageal stricture, or malignancy
• • Severe gastroparesis or esophageal motility disorder unrelated to achalasia
• • Pregnancy or breastfeeding
• • Severe hepatic or renal impairment (ALT/AST \>3× ULN, eGFR \<30 mL/min)
• • Regular use of NSAIDs, steroids, or anticoagulants affecting esophageal healing